Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I guess that with the separate enolase patent for autoimmune disease, Scancell wanted to emphasise that they had the patent for cancer treatment.
I assume Karolinska are looking at ways of blocking the enolase epitopes.
Perhaps Moditope is giving them clues as to how to do this.
Who knows, Avidimab may also help in this area.
Mabs to block the enolase epitopes i.e not binding to APCs but binding to the areas affected by RA.
The enolase patent is held by the Karolinska Institutet but for autoimmune decease hence scancell had to get agreements and apply for another patent for Cancer
Ray,
I've wondered about that too. I thought Scancell had previously said that the original Moditope patent covered any citrullinated peptide but perhaps I'm not remembering correctly.
Bermuda
Do we know why Scancell considered that a patent specifically for enolase citrullinated peptides was required over and above the previous Moditope patent.
Thanks Bermuda, much appreciated, that makes a lot more sense now.
This paragraph you wrote at least gives a little bit of positivity/hope!
"....We now know the European Enolase patent is about to be granted which must give hope for the US counterpart. Also the European divisional application for the DNA version of Moditope has recently been re-examined and revised claims were submitted at the end of October. Hopefully that one is now very close to being granted too."
WTP
Konar is your best bet for the answer to this one but my take is as follows.
It's a long-winded process whereby the application undergoes examination, the examiner raises objections and then Scancell argue their case or amend the claims to overcome those objections. That can happen several times over for each patent office. AFAIK there is nothing to suggest that all O/S patents won't eventually be granted although there may still be some amendments to the claims but obviously it's completely down to the examiner in each jurisdiction.
We now know the European Enolase patent is about to be granted which must give hope for the US counterpart. Also the European divisional application for the DNA version of Moditope has recently been re-examined and revised claims were submitted at the end of October. Hopefully that one is now very close to being granted too.
In answer to your final question, I just don't know whether any potential partner would need to see all patents granted before making any move, nor do I know how important the screening divisional application is to Scancell. I would have thought that any deal could be structured to cover any O/S patents but WDIK?
ps. Inanaco, last sentence of this post was a rhetorical one, no need for any answers :)
Bermuda, I was going to ask earlier on here where things stand RE the patent announcement today, and then i noticed you replied to goosed's question over on ADVFN, hope you don't mind but I've taken the liberty of copying it here as im sure it's helpful for others too:
"...goooosed, Intention to grant the enolase patent was originally flagged by Konar and discussed on lse a while ago so not exactly new news. AFAIK the situation with the various Moditope patent applications is as follows:-
1) Original Moditope patent now granted in Europe, US and most major jurisdictions, nb. DNA version split off into new, divisional/continuation applications (see no. 3 below)
2) An additional application was filed by Scancell back in 2016 to cover citrullinated enolase peptides. European Patent Office gave notice of their intention to grant this patent at the end of October, still pending in other jurisdictions. This application is the subject of today's RNS.
3) Two divisional patent applications have been filed with the European Patent Office and one continuation application in the US - these are linked to the original application. They cover the DNA version of Moditope. Also, one of the European divisionals covers a screening process to identify and sort CD4 T cells from patients blood, think this relates to Modi TCR. None of these applications have yet been granted. Shame Konar isn't around, he is the expert!"
Just to add to goosed's question, does this mean the grants should in theory happen now/eventually? I.e. a given? And does it help to cross the t's and dot the i's "if" a potential suitor was thinking "...mmm i like scancell but they better sure have those patents granted before we make an offer!"?